Welcome to the UCL Cancer Institute
The UCL Cancer Institute is the hub for cancer research at University College London, one of the World's leading universities. The Institute draws together over 300 talented scientists who are working together to translate research discoveries into developing better, more effective therapies for cancers and improve outcomes for cancer patients. If you are thinking about postgraduate study with us, applications to our flagship MSc Cancer programme are now open for the academic year 2017/18, or find our more about our postgraduate research.
News and features
A research team, led by UCL, has published the results of a highly anticipated clinical trial comparing platinum and non-platinum chemotherapy in the Journal of Clinical Oncology. The aim of this trial was to see whether doctors could select the most effective chemotherapy treatment for advanced lung cancer patients.
Published: Jan 13, 2017 12:07:27 PM
A new non-surgical treatment for early, low-risk prostate cancer can effectively kill cancer cells while preserving healthy tissue, reports a new phase III clinical trial in 413 patients led by Professor Mark Emberton, Dean of UCL Medical Sciences and consultant urologist at UCLH. The trial was funded by STEBA Biotech which holds the commercial license for the treatment.
Published: Dec 20, 2016 10:16:16 AM
The UCL Cancer Research UK Centre, led by Professors Daniel Hochhauser and Henning Walczak, and UCL's Experimental Cancer Medicine Centre (ECMC), led by Professors Tim Meyer and John Hartley, have successfully secured new funding as part of a £226 million UK investment announced by Cancer Research UK.
Published: Dec 20, 2016 9:46:32 AM
Research led by UCL and Queen Mary University of London (QMUL) scientists has identified epigenetic changes in three types of immune cell that could contribute to the development of type 1 diabetes. These changes were only found in patients with diabetes, opening the door to future biomarker development. The study, published today in Nature Communications, employed a unique experimental design that can now allow researchers to more confidently interpret results from epigenomic studies.
Published: Nov 29, 2016 6:45:50 PM
Professor Ultan McDermott, Sanger Institute Cambridge, presents: Forward genetics to identify novel targets and overcome drug resistance in cancer
Starts: Jan 26, 2017 12:00:00 PM
Dr Sergio Quezada presents: The Battle Within: mobilising our immune system to fight cancer.
Starts: Feb 21, 2017 1:15:00 PM
An introductory course aimed at recent MSc graduates or experienced statisticians new to the field of cancer trials.
Starts: Mar 8, 2017 9:30:00 AM
Support our work
Help us to continue the research that will lead to the breakthroughs in cancer therapies that will benefit the lives of cancer patients.